De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions

Niccolò E. Mencacci, Erik-Jan Kamsteeg, Kosuke Nakashima, +28

The American Journal of Human Genetics

TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice

Hiroshi Yukitake, Tatsuhiko Fujimoto, Takashi Ishikawa, +6

Pharmacology Biochemistry and Behavior

Molecular PhysiologySignal TransductionFunctional SelectivityMedicinePhysiology +9

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

Rebecca Evans, Haruhide Kimura, Robert Alexander, +11

Proceedings of the National Academy of Sciences

Sleep DisordersNarcolepsy PhenotypePharmacotherapyNarcolepsy Type 1Experimental Pharmacology +17

A homozygous <i>loss‐of‐function</i> mutation in <i>PDE2A</i> associated to early‐onset hereditary chorea

Vincenzo Salpietro, Belén Pérez‐Dueñas, Kosuke Nakashima, +12

Movement Disorders

Discovery of 1-[2-Fluoro-4-(1<i>H</i>-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1<i>H</i>-pyrazol-5-yl)pyridazin-4(1<i>H</i>)-one (TAK-063), a Highly Potent, Selective, and Orally Active Phosphodiesterase 10A (PDE10A) Inhibitor

Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi, +10

Journal of Medicinal Chemistry

Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry +17

TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms

Kazunori Suzuki, Akina Harada, Hirobumi Suzuki, +2

Neuropsychopharmacology

NeuropsychologyPsychoactive DrugPsychiatryMultiple ParadigmsMedicine +10

TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects

Yuu Sako, Emi Kurimoto, Takao Mandai, +6

Neuropsychopharmacology

Low CooperativityMolecular PharmacologyMolecular NeuroscienceFunctional SelectivityMedicine +8

In Vivo Pharmacological Characterization of TAK-063, a Potent and Selective Phosphodiesterase 10A Inhibitor with Antipsychotic-Like Activity in Rodents

Kazunori Suzuki, Akina Harada, Eri Shiraishi, +1

Journal of Pharmacology and Experimental Therapeutics

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models

E. Shiraishi, Kazunori Suzuki, Noriko Suzuki, +1

Journal of Pharmacology and Experimental Therapeutics

T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice

Satoru Matsuda, Rina Baba, Hideyuki Oki, +14

Neuropsychopharmacology

Specific InhibitorMedicineImmunologyNeuroscienceLsd1 Enzyme Activity +2